102 related articles for article (PubMed ID: 6609349)
1. [Natural cytotoxicity in patients with Hodgkin's disease].
Frydecka I; Budzyński W; Kuliczkowski K; Rybczyńska H
Pol Tyg Lek; 1983 Oct 17-24; 38(42-43):1309-12. PubMed ID: 6609349
[No Abstract] [Full Text] [Related]
2. [Cytotoxic activity of K-lymphocytes (killer cells) in Hodgkin's disease].
Górska B; Konopka L; Seyfried H; Pawelski S
Pol Tyg Lek; 1980 Aug; 35(33):1249-51. PubMed ID: 7433209
[No Abstract] [Full Text] [Related]
3. Natural killing in normal children and children with Hodgkin's disease.
Kamiya H; Starr S; Lange B
Am J Pediatr Hematol Oncol; 1985; 7(4):389-92. PubMed ID: 4083399
[No Abstract] [Full Text] [Related]
4. [Lymphocyte subpopulations in malignant growths].
Kadagidze ZG
Vopr Onkol; 1984; 30(1):90-7. PubMed ID: 6198804
[No Abstract] [Full Text] [Related]
5. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
Böll B; Eltaib F; Reiners KS; von Tresckow B; Tawadros S; Simhadri VR; Burrows FJ; Lundgren K; Hansen HP; Engert A; von Strandmann EP
Clin Cancer Res; 2009 Aug; 15(16):5108-16. PubMed ID: 19671844
[TBL] [Abstract][Full Text] [Related]
6. [Activity of T, NK and K lymphocytes in two immunodeficiency syndromes].
Olìnescu A; Hristescu S; Poliopol M; Agachi F
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1987; 39(2):185-92. PubMed ID: 2888179
[No Abstract] [Full Text] [Related]
7. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease.
Kanavaros P; Vlychou M; Stefanaki K; Rontogianni D; Gaulard P; Pantelidaki E; Zois M; Darivianaki K; Georgoulias V; Boulland ML; Gorgoulis V; Kittas C
Anticancer Res; 1999; 19(2A):1209-16. PubMed ID: 10368677
[TBL] [Abstract][Full Text] [Related]
8. [Immune monitoring of the cancer patient: suppressor cells and NK cells].
Goutner A; Thomas Y; Huchet R; Mathé G
C R Seances Soc Biol Fil; 1980; 174(4):750-5. PubMed ID: 6159953
[TBL] [Abstract][Full Text] [Related]
9. Generation of lymphokine-activated killer cells with veto and natural suppressor activity from patients with leukemias and lymphomas.
Cheruku R; Uberti J; Martilotti F; Kaplan J
Transplantation; 1993 Oct; 56(4):1037-40. PubMed ID: 8212188
[No Abstract] [Full Text] [Related]
10. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro.
Katznelson S; Wang XM; Chia D; Ozawa M; Zhong HP; Hirata M; Terasaki PI; Kobashigawa JA
J Heart Lung Transplant; 1998 Apr; 17(4):335-40. PubMed ID: 9588577
[TBL] [Abstract][Full Text] [Related]
11. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression.
Kelley TW; Pohlman B; Elson P; Hsi ED
Am J Clin Pathol; 2007 Dec; 128(6):958-65. PubMed ID: 18024321
[TBL] [Abstract][Full Text] [Related]
12. [Natural killer cell activity in diffuse panbronchiolitis].
Yoshimura K; Chonabayashi N; Nakatani T; Nakamori Y; Nakata K; Tanimoto H
Arerugi; 1986 Apr; 35(4):275-81. PubMed ID: 3488726
[No Abstract] [Full Text] [Related]
13. [K (killer) cell activity in lymphogranulomatosis].
Láng I; Berényi E; Szegedi G; Fekete B; Török K; Kalmár L; Nékám K
Orv Hetil; 1978 Sep; 119(37):2249-50. PubMed ID: 308627
[No Abstract] [Full Text] [Related]
14. Functional analysis of peripheral blood lymphocytes from healthy volunteers.
Donnerstag B; Oltrogge JB; Henzel K; Rüenauver A; Baum RP
J Clin Lab Immunol; 1993; 40(2):91-5. PubMed ID: 7932632
[TBL] [Abstract][Full Text] [Related]
15. [The natural killer cell activity and count of large granule-containing lymphocytes in the blood of patients with malignant lymphomas].
Zlochevskaia LL; Kindzel'skiĭ LP; Shabaeva MM; Tsyganok TV
Vrach Delo; 1990 Feb; (2):36-9. PubMed ID: 2339548
[TBL] [Abstract][Full Text] [Related]
16. Characterization of recirculating lymphocytes in rheumatoid arthritis patients: selective deficiency of natural killer cells in thoracic duct lymph.
Fox RI; Fong S; Tsoukas C; Vaughan JH
J Immunol; 1984 Jun; 132(6):2883-7. PubMed ID: 6609962
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell numbers and cytotoxic activity in pediatric Hodgkin disease.
Ikincioğullari A; Doğu F; Babacan E; Oflaz G; Ertem U; Yavuz G; Unal E; Gözdaşoğlu S; Taçyildiz N; Dağdemir A; Cavdar AO
Pediatr Hematol Oncol; 2000 Mar; 17(2):133-9. PubMed ID: 10734655
[TBL] [Abstract][Full Text] [Related]
18. Natural killer (NK) activity in the spleen of patients with Hodgkin's disease and controls.
Al Sam S; Jones DB; Payne SV; Wright DH
Br J Cancer; 1982 Nov; 46(5):806-10. PubMed ID: 7171458
[No Abstract] [Full Text] [Related]
19. Impaired natural killer cell activity in patients with inflammatory bowel disease: evidence for a qualitative defect.
Ginsburg CH; Dambrauskas JT; Ault KA; Falchuk ZM
Gastroenterology; 1983 Oct; 85(4):846-51. PubMed ID: 6884709
[TBL] [Abstract][Full Text] [Related]
20. The effect of peripheral blood lymphocyte stimulation on zeta chain expression and IL-2 production in Hodgkin's disease.
Frydecka I; Boćko D; Kosmaczewska A; Ciszak L; Morilla R
Br J Cancer; 2001 May; 84(10):1339-43. PubMed ID: 11355944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
